若生智能
Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · 疫苗 · 疫苗

什么是 measles vaccine (live-attenuated)？

measles vaccine (live-attenuated) 是一种疫苗，由Beijing Tiantan Biological Products研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Beijing Tiantan Biological Products
药物类别疫苗, 大分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Beijing Tiantan Biological Products

治疗适应症

measles vaccine (live-attenuated) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeasles✓ Approved

相关研究文献

PubMedVaccines2026-07-27

A Repeated and Delayed Homologous Challenge Study Evaluating the Durability of Protection Induced by the Live Attenuated ASF Vaccine Candidate ASFV-G-ΔI177L/ΔLVR.

Zheng Xinghua X, Kim Yeonji Y, Choi Sun A SA, Lee Su Jin SJ et al.

African swine fever (ASF) is a highly lethal disease of domestic pigs and wild suids that continues to cause substantial economic losses worldwide. Despite recent progress in live attenuated ASF vaccine development, evidence supporting durable protection under repeated exposure conditions representative of endemic settings remains limited. Here, we assessed the long-term safety and protective efficacy of a live attenuated ASFV-G-ΔI177L/ΔLVR vaccine using a repeated-challenge experimental design intended to model re-exposure in ASF-endemic regions. Vaccinated pigs were subjected to homologous virulent ASF virus challenges at multiple intervals, including repeated challenges (three sequential inoculations) and single challenges administered at 8 and 12 weeks post-vaccination. Across all challenge regimens, vaccinated animals survived and remained clinically healthy, including those receiving three challenges, supporting sustained protection under repeated exposure pressure. Animals challenged at 8 or 12 weeks post-vaccination likewise exhibited complete survival, indicating maintained efficacy through at least 12 weeks. No vaccine-associated adverse clinical outcomes were detected over the study period, and post-challenge viral shedding was minimal. Overall, these data demonstrate that the candidate live attenuated ASF vaccine provides excellent protective efficacy and confers sustained protection against homologous ASF virus infection. This result is expected to be equally applicable under repeated exposure conditions in regions with unstable ASF biosecurity, making it a sufficiently promising model experiment for field application in ASF epidemic areas. However, this is still a vaccine variant, and further studies are planned to evaluate its genomic stability and transmissibility.

PMID 42506598
阅读全文 →
PubMedVaccines2026-07-27

Understanding Measles in Hospitalized Adults: Insights into the Recent Romanian Epidemic, Clinical Presentation and Perspectives on MMR Vaccination Among Roma Hospitalized Patients.

Mangaloiu David Valentin DV, Halvorsen Dag S DS, Raris Alexandra Denisa AD, Ștefan Aramă Sorin AS et al.

Measles remains a significant public health concern in Romania, with recurrent ongoing nationwide outbreaks despite the availability of the measles-mumps-rubella (MMR) vaccine. This study investigates the epidemiological, clinical, and sociocultural dimensions of measles among Romanian adults, with a particular focus on a vulnerable group, the Roma population. We conducted a retrospective cohort study using clinical data from a tertiary hospital in Bucharest, Romania. The study included adult patients hospitalized with measles between July 2023 and April 2024. In a subsequent phase, we carried out a cross-sectional survey among hospitalized measles patients to assess their perception and understanding of measles and the MMR vaccine, with particular attention to responses from Roma participants. A retrospective investigation of 100 hospitalized adult patients with laboratory-confirmed diagnoses of measles demonstrated frequent complications such as hepatic involvement (85/100), pneumonia (68/100), and respiratory failure (21/100). Only 6/100 of patients were fully vaccinated. Rhabdomyolysis was significantly more common in unvaccinated individuals and women. No deaths were recorded, and no ICU admissions occurred. Among the hospitalized patients, 49 adults responded to a vaccine centered questionnaire. We report a notable vaccine hesitancy, particularly among the Roma respondents. Socioeconomic factors such as low income, limited education, and lack of health insurance were significantly associated with negative perceptions of the MMR vaccine. A statistically significant association was observed between Roma ethnicity and the belief that the MMR vaccine causes autism. These findings highlight the urgent need for targeted public health interventions with culturally adapted education campaigns to improve vaccination coverage and thereby protect vulnerable adult populations in Romania.

PMID 42506649
阅读全文 →
PubMedVaccines2026-07-27

Evaluation of Safety, Immunogenicity, and Protective Efficacy of an Orally Administered African Swine Fever Vaccine Candidate ASFV-G-∆I177L/∆LVR.

Kim Yeonji Y, Choi Sun A SA, Kim Wonjun W, Shin Yongwoo Y et al.

Background/Objective: African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious viral disease affecting domestic pigs and wild boars, causing severe economic losses. Although commercial ASF vaccines have recently been approved in Vietnam, controlling ASF transmission remains challenging. Since injection-based vaccination is impractical for wild boars, oral vaccination is considered essential. This study aimed to evaluate the safety, immunogenicity, protective efficacy, and dose-related outcomes of ASFV-G-ΔI177L/ΔLVR, a live attenuated ASFV vaccine candidate with deletion in the I177L gene and left variable region (LVR), administered orally to convention pigs. Methods: The ASFV-G-ΔI177L/ΔLVR vaccine candidate was orally administered to conventional pigs at three dose levels (102.25, 105.0, and 106.0 TCID50/dose). At 28 days post-vaccination, pigs were challenged intramuscularly with a virulent ASFV field strain at 102.0 HAD50/mL and monitored clinically. Protection was assessed by ASFV-specific antibody responses (p32) and survival following challenge. Results: Oral immunization was well tolerated, with no vaccine-associated clinical signs observed before challenge. Following challenge, vaccinated pigs showed different protective outcomes among the tested dose groups, with survival rates of 1/4 (102.25 TCID50/dose), 4/4 (105.0 TCID50/dose), and 3/4 (106.0 TCID50/dose), respectively. Pigs that succumbed to infection showed neither detectable viremia nor ASFV-specific antibodies before challenge, suggesting incomplete vaccine uptake may have resulted in insufficient immune induction rather than an adverse effect associated with vaccination. In contrast, pigs that seroconverted prior to challenge were fully protected and exhibited lower viral loads than the control animals. Conclusions: ASFV-G-ΔI177L/ΔLVR was well tolerated as an oral live attenuated vaccine candidate and induced protective immunity against virulent ASFV challenge under the present experimental conditions. Notably, complete protection was observed in the 105.0 TCID50/dose group, supporting the potential of this vaccine candidate for oral immunization strategies against ASF. However, the present data do not allow a definitive conclusion regarding the dose-response relationship, and further studies with larger group sizes and field-relevant models are needed to refine dose selection and practical applicability, particularly for wild boar vaccination.

PMID 42506646
阅读全文 →
PubMedVaccines2026-07-27

Development of a New Feline Combination Vaccine Including a Novel RNA Particle Vaccine Against Feline Leukemia Virus.

Huisman Willem W, Mommen Aart A, Basten Stephanie S, Driessen Kim K et al.

We describe the rationale, design and evaluation of a novel feline combination vaccine (Nobivac® NXT HCPChFeLV) incorporating RNA particle technology against feline leukemia virus (FeLV) alongside live attenuated components for feline herpesvirus-1 (FHV), feline calicivirus (FCV), feline panleukopenia (FPL) and Chlamydia felis. Efficacy and safety outcomes from laboratory and field studies are presented. Nobivac NXT HCPChFeLV is a 0.5 mL, non-adjuvanted, lyophilized vaccine containing live attenuated FHV, FCV, FPL, and C. felis strains, and an alphavirus replicon-derived RNA particle expressing FeLV envelope glycoprotein (gp85). The primary vaccination schedule involved subcutaneous vaccination at 8-9 weeks of age with a booster 4 weeks later. Onset-of-immunity studies were performed 1 week post primary vaccination. Duration-of-immunity studies evaluated challenge both at 1 year and 3 years after primary vaccination with a booster at 1 year (FHV, FCV, FeLV); FPL duration was assessed at 3 years after primary vaccination; C. felis duration was assessed at 1 year. Clinical signs of disease, survival, leukopenia (FPL) and pathogen excretion were assessed. Safety was assessed in laboratory overdose/repeat-dose studies and in a field study comparing concurrent (non-mixed) use with rabies vaccination vs a positive control regimen. Vaccination significantly reduced clinical disease following FHV, FCV and C. felis challenge and reduced FHV-associated mortality. Vaccinated cats were protected from FPL clinical disease, mortality, leukopenia, and FPL excretion. Persistent FeLV antigenemia was significantly prevented after primary vaccination and in 1-year-duration-of-immunity studies and was reduced 3 years after revaccination. The excretion of FHV, FCV and C. felis was significantly reduced in vaccinates vs controls. No serious adverse events were observed in laboratory studies; field vaccination was well tolerated with no injection-site reactions reported. Nobivac NXT HCPChFeLV provides robust, long-lasting protection against multiple feline pathogens, reduced pathogen shedding and demonstrated a favorable safety profile, supporting its use in feline preventive healthcare.

PMID 42506662
阅读全文 →
PubMedEmerging microbes & infections2026-07-27

Human pulmonary infection by Brucella suis vaccine strain S2 revealed by genome sequencing in China.

Li Kun K, Zhou Xiaoyan X, Tian Lingling L, Wu Leyu L et al.

Brucellosis the most common zoonosis worldwide. For control and prevention of animal brucellosis, various Brucella vaccines have been developed. Brucella suis S2, a live attenuated vaccine strain proven safe to humans, is widely used in China. In this report, a 77-year-old woman with a history of coughing and expectoration for three years was diagnosed with brucellosis by next-generation sequencing. Subsequently, the Brucella isolate from this patient was determined to be Brucella suis vaccine strain S2 by phage lysis experiments, quantitative real-time PCR, and third-generation sequencing. Its nucleotide identity with vaccine strain S2 was as high as 99.9996%, and only 14 deletion/insertion mutations or single nucleotide polymorphisms were detected. A phylogenetic tree constructed based on the genome sequences revealed that this strain clustered together with strain S2. As the patient denied having a history of contact with animals or exposure to other known sources, an epidemiological investigation was carried out on environmental and food samples. The results did not reveal a clear infection source except for a B. suis S2-like strain (99.9939% identity to B. suis S2 strain) from a milk sample. Our study may provide the first reliable evidence that B. suis vaccine strain S2 has the potential to infect humans. While this needs further confirmation, it points to the need to survey the virulence and risks of vaccine strain S2 in humans. In addition, the route of transmission of vaccine strain S2 still needs to be clarified to prevent more cases of brucellosis originating from this strain.

PMID 42504691
阅读全文 →
PubMedVaccines2026-07-27

Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios.

Zhang Wei W, Li Song S, Yan Tianming T, Zhou Congjun C et al.

The aim was to evaluate the cost-effectiveness of self-paid vaccination using Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV) in China, as well as their inclusion in China's National Immunization Program (NIP), and to determine the most cost-effective initial vaccination age under this inclusion strategy. Based on the ZONA model, a Markov model was developed by incorporating pain severity levels for herpes zoster (HZ) and postherpetic neuralgia (PHN), allowing for dynamic transitions between health states. The model evaluated the cost-effectiveness of six vaccination strategies from a societal perspective. Economic evaluations were conducted using the incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and incremental cost-utility ratio (ICUR). The robustness of the results was verified through sensitivity analysis. In the self-paid scenario, both RZV and ZVL were economically viable for preventing HZ. However, neither was cost-effective in preventing PHN. When included in the NIP, initiating RZV vaccination at age 50 demonstrated dominance (higher quality-adjusted life years and lower costs), with an ICER of -3826 CNY per HZ case prevented, -38,669 CNY per PHN case prevented, and an ICUR of -11,128 CNY per QALY gained. Subgroup analysis indicated that initiating RZV vaccination at age 50 offered the best cost-effectiveness, while age 70 was the most cost-saving option. Generally, RZV demonstrates greater cost-effectiveness compared to ZVL. Incorporating RZV into the NIP, starting at age 70, is the optimal strategy to reduce the burden of HZ and PHN and improve healthcare resource allocation in China.

PMID 42506624
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多measles vaccine (live-attenuated)